Structure Therapeutics, Inc. · NASDAQ:GPCR

Structure Therapeutics — Corporate Update (June 2024)

31 slides from Structure Therapeutics's corporate update, Jun 3, 2024

  1. Slide 1: GSBR-1290 Obesity Topline Data Presentation

    1 GSBR-1290 Obesity Topline Data Presentation June 2024

  2. Slide 2: Disclaimers and Forward Looking Statements

    2 Disclaimers and Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed

  3. Slide 3: Agenda

    3 Agenda Opening Remarks and Overview Raymond Stevens, Ph.D. Chief Executive Officer GSBR-1290 Obesity Topline Data • Efficacy Summary • Safety and Tolerability Summary • Pharmacokinetic (PK) summary Blai Coll, M.D., Ph.D. VP Clinical Development GSBR-1290 Planned Next Steps • Phase 2b 36-week Obesi

  4. Slide 4: Our Mission is to Make Medicines More Accessible to All

    4 Our Mission is to Make Medicines More Accessible to All PEPTIDE OR BIOLOGIC MEDICINES ACCESSIBLE FOR ALL ORAL SMALL MOLECULE

  5. Slide 5: GSBR-1290 Obesity Data Position for Potential Best-in-Class Oral GLP-1RA

    5 We believe GSBR-1290 Obesity Data Position for Potential Best-in-Class Oral GLP-1RA Best-in-Class Criteria GSBR-1290 Performance through Phase 2a Competitive Efficacy 6.2 – 6.9% placebo-adjusted weight loss at 12 weeks Safety No liver liability Large safety window – potential to go higher in dose

  6. Slide 6: GSBR-1290 Obesity Topline Results: Efficacy Summary

    6 GSBR-1290 Obesity Topline Results Efficacy Summary

  7. Slide 7: GSBR-1290 Phase 2a Study Design in Overweight or Obese Participants

    7 GSBR-1290 Phase 2a Study Design in Overweight or Obese Participants 5 mg 15 mg 30 mg 60 mg 90 mg 120 mg Follow up 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 weeks PBO PBO PBO PBO PBO PBO Follow up (n=37) (n=27) Healthy Overweight / Obese Participants N= 64* * Cohort of 24 participants added as replacement

  8. Slide 8: GSBR-1290 Phase 2a Study Baseline Characteristics

    8 GSBR-1290 Phase 2a Study Baseline Characteristics Phase 2a Obesity Study (12 week) N=64, Randomized GSBR-1290 capsule Characteristics Mean (SD) or N (%) 120 mg (N=37) Placebo (N=27) Age, years 45.1 (14.3) 44.7 (12.0) Sex, female, N (%) 20 (54.1) 11 (40.7) Hispanic or Latino, N (%) 16 (43.2) 13 (48

  9. Slide 9: Phase 2a Results: Significant Weight Loss Observed at 12 Weeks

    9 • 6.2% placebo-adjusted weight loss observed after 12 weeks • Statistically significant weight reduction over 12 weeks with a clear separation compared to placebo GSBR-1290 120 mg % Change in Body Weight, placebo-adjusted -6.2 95% Confidence Interval (CI) -8.9, -3.6 P-value vs placebo* <0.0001 GSB

  10. Slide 10: Two Thirds of Participants Reported at least 6% Weight Loss

    10 • 67% participants receiving GSBR-1290 achieved at least a 6% weight loss • 33% achieved at least a 10% weight loss • 0% of participants receiving placebo achieved at least a 5% weight loss 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% ≥ 6% ≥ 8% ≥ 10% Percentage of GSBR-1290 dosed participants achi

  11. Slide 11: GSBR-1290 Capsule to Tablet PK Study Design

    11 GSBR-1290 Capsule to Tablet PK Study Design Healthy Overweight / Obese Participants N= 54 * Cohort 3 15:3 PBO Screening 5mg 15mg 30mg 60mg capsule 60mg tablet Follow up 60mg tablet 60mg capsule -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Cohort 2 15:3 PBO Screening 15mg 30mg 60mg 90mg 120mg Fo

  12. Slide 12: Capsule to Tablet PK Study Results: Significant Weight Loss with Tablet

    12 GSBR-1290 120 mg (C1) GSBR-1290 120 mg (C2) GSBR-1290 60 mg (C3) % Change in Body Weight, placebo-adjusted -6.9 -6.8 -6.2 95% CI -9.4, -4.3 -9.4, -4.2 -8.8, -3.7 P-value vs placebo* <0.0001 <0.0001 <0.0001 -7 -6 -5 -4 -3 -2 -1 0 1 2 0 2 4 6 8 10 12 Body Weight Change From Baseline (%) LSM ± SE We

  13. Slide 13: GSBR-1290 Obesity Data Compare Favorably to Other Oral Selective GLP-1RAs

    13 GSBR-1290 Obesity Data Compare Favorably to for Other Oral Selective GLP-1RAs Peptide Selective GLP-1R Agonist Sample size indicate total number of subjects enrolled study drug and placebo ☨ Indicates approximate 12 week weight loss, extrapolated by the Company using data from 36 week study (Orfo

  14. Slide 14: GSBR-1290 Obesity Topline Results: Safety and Tolerability

    14 GSBR-1290 Obesity Topline Results Safety and Tolerability

  15. Slide 15: GSBR-1290 Phase 2a Study Participant Disposition

    15 GSBR-1290 Phase 2a Study Participant Disposition Phase 2a Obesity Study (12 week) N=64, Randomized GSBR-1290 capsule Number of Participants Reporting N (%) 120mg (N=37) Placebo (N=27) Discontinued study not due to AEs 5 (13.5) 1 (3.7) Discontinued study due to AEs related to treatment 2 (5.4)* 0

  16. Slide 16: Phase 2a Safety and Tolerability: GI AEs Most Common in Rapid Titration

    16 Participants with at least one event during 12 week period, N (%) 120 mg (N=37) Placebo (N=27) Serious Adverse Events 0 0 Nausea Mild Moderate Severe 33 (89.2) 15 (40.5) 18 (48.6) 0 3 (11.1) 3 (11.1) 0 0 Vomiting 23 (62.2) 1 (3.7) Constipation 16 (43.2) 4 (14.8) Decreased appetite 15 (40.5) 3 (11

  17. Slide 17: Liver Safety and Serious Adverse Events Across Studies

    17 Phase 2a Obesity Study (GSBR-1290 capsule) Capsule to Tablet PK Study (GSBR-1290 tablet) Number of Participants Reporting N (%) 120 mg (N=37) Placebo (N=27) 120 mg (C1, C2) (N=30) 60 mg (C3) (N=15) Placebo (N=9) Serious Adverse Events 0 0 0 0 0 Drug Induced Liver Injury (DILI) 0 0 0 0 0 Hepatic e

  18. Slide 18: GSBR-1290 PK Summary and Comparability of Capsule to Tablet Formulation

    18 GSBR-1290 PK Summary and Comparability of Capsule to Tablet Formulation

  19. Slide 19: GSBR-1290 Overall Properties Confirm Once Daily Dosing

    19 GSBR-1290 Overall Properties Confirm Once Daily (QD) Dosing * Median (min-max) ** At 24h post-dose *** The T1/2 at Day 49 in the capsule study @120 mg does not capture samples beyond 24h (half-life value might be underestimated) *10 ng/mL threshold identified through NHP studies that demonstrated

  20. Slide 20: GSBR-1290 Next Steps and Summary: Phase 2b Obesity Study

    20 GSBR-1290 Next Steps and Summary Phase 2b Obesity Study (36 week)

  21. Slide 21: Capsule to Tablet PK Study Key Learnings Inform Phase 2b Design

    21 Capsule to Tablet PK Study Key Learnings Inform Phase 2b Study Design % of participants reporting at least one event 0% 10% 20% 30% 40% 50% 60% 70% 80% 5 mg 10 mg 15 mg 5 mg 20 mg 30 mg First week Second week Nausea Vomiting Go Slow Start Low Week 1 Participants receiving 5 mg associated with low

  22. Slide 22: GSBR-1290 Phase 2b Obesity Study Anticipated to Initiate in Q4 2024

    22 GSBR-1290 Multiple maintenance doses Placebo R ~ 300 participants Obesity: BMI ˃ 30 Overweight: BMI ˃ 27 with comorbidity Phase 2b Dose Selection on going Start Low, Go Slow • Lower 5mg starting dose • Slower 4 week titration to optimize tolerability • Preclinical and clinical safety data enables

  23. Slide 23: New GSBR-1290 Obesity Data Demonstrate Potential Best-in-Class Profile

    23 New GSBR-1290 Obesity Data Demonstrate Potential Best-in-Class Profile Foundational Backbone Asset in Oral Small Molecule Metabolic Portfolio EFFICACY RESULTS 6.2% placebo-adjusted weight loss at 12 weeks in Phase 2a Obesity 6.2 to 6.9% placebo-adjusted weight loss at 12 weeks with new tablet for

  24. Slide 24: GSBR-1290 Opportunity

    24 GSBR-1290 Opportunity

  25. Slide 25: 12-week Data Positions GSBR-1290 as Potential Best-in-Class Oral GLP-1RA

    25 12-week Data Positions GSBR-1290 as Potential Best-in-Class Oral GLP-1RA Boye et al, 2021 Diabetes Obesity Metabolism https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839441/ 23.5% 76.5% >75% of patients initially preferred a daily oral medication over a weekly injectable1 Weekly Injection Daily Ora

  26. Slide 26: Committed to Developing Oral Small Molecules for a Very Large Obesity Population

    26 1. 2022 World Health Organization https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight 2. Trust for America’s Health Report https://www.tfah.org/report-details/stateofobesity2019/#:~:text=Obesity%20is%20a%20growing%20epidemic,100%20million%20people%20%E2%80%93%20have%20obesity.

  27. Slide 27: We Believe GSBR-1290 can be Commercially Manufactured at Scale

    27 We Believe GSBR-1290 can be Commercially Manufactured at Scale ~6,000 tons • Synthetic route locked and ready for planned batches • Manufacturing of Phase 2b GMP supply completed1 • Current manufacturing capacity of 6,000 tons/year to supply >120M patients 0.001 0.01 0.1 1 10 100 1000 10000 10000

  28. Slide 28: GSBR-1290 Obesity Data Position for Potential Best-in-Class Oral GLP-1RA

    28 We believe GSBR-1290 Obesity Data Position for Potential Best-in-Class Oral GLP-1RA Best-in-Class Criteria GSBR-1290 Performance through Phase 2a Competitive Efficacy 6.2 – 6.9% placebo-adjusted weight loss at 12 weeks Safety No liver liability Large safety window – potential to go higher in dose

  29. Slide 29: Where does GSBR-1290 fit in the GLP-1RA landscape?

    29 Number of patients with access Where does GSBR-1290 fit in the GLP-1RA landscape? Phase 2a Proof of Concept 12 weeks Phase 2b Dose Range Finding 36 weeks Phase 3 Pivotal 52+ Weeks AmylinR, GIPR, GCGR, APJR GSBR Oral Combinations with GSBR-1290 -1290 Aspirational Targets1 • Mid to High Teen Percen

  30. Slide 30: Strong Momentum with Multiple Potential Catalysts in 2024 – 2026

    30 Strong Momentum with Multiple Potential Catalysts in 2024 – 2026 1H 2024 1H 2025 GSBR-1290 (Oral GLP-1R) Phase 2a Data June Oral GIPR Anticipated Milestones – Entire Oral Small Molecule Portfolio ANPA-0073 (Oral APJR) Phase 2 Ready LTSE-2578 (Oral LPA1R) Phase 1 Data 2H 2025 Phase 1 Start June 20

  31. Slide 31: Thank you

    31 Thank you ir@structuretx.com www.structuretx.com

Structure Therapeutics — Corporate Update (June 2024) on 6ix